| Code | CSB-RA2267MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to ARGX-118, targeting the Charcot-Leyden crystal (CLC) protein, also known as galectin-10. CLC is predominantly expressed in eosinophils and basophils, where it constitutes a significant portion of cellular protein content. Upon degranulation of these cells, CLC is released into tissues and can crystallize, forming characteristic bipyramidal crystals that serve as hallmarks of eosinophilic inflammation. This protein plays a crucial role in type 2 inflammatory responses and has been implicated in various allergic and eosinophilic disorders, including asthma, chronic rhinosinusitis, eosinophilic esophagitis, and hypereosinophilic syndromes.
ARGX-118 represents a therapeutic antibody approach aimed at neutralizing CLC to modulate eosinophil-driven inflammation. As a research-grade biosimilar, this antibody provides investigators with a valuable tool for studying CLC biology, eosinophil function, and the pathophysiology of type 2 inflammatory diseases. It supports investigations into novel therapeutic strategies for conditions characterized by aberrant eosinophil activation and tissue infiltration.
There are currently no reviews for this product.